CA3017477A1 - Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder - Google Patents

Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder

Info

Publication number
CA3017477A1
CA3017477A1 CA3017477A CA3017477A CA3017477A1 CA 3017477 A1 CA3017477 A1 CA 3017477A1 CA 3017477 A CA3017477 A CA 3017477A CA 3017477 A CA3017477 A CA 3017477A CA 3017477 A1 CA3017477 A1 CA 3017477A1
Authority
CA
Canada
Prior art keywords
cells
composition
immunoglobulin preparation
colostrum
lps enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3017477A
Other languages
English (en)
French (fr)
Inventor
Yaron Ilan
Gadi Lalazar
Tomer Adar
Meir Mizrahi
Ami Ben-Ya'acov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immuron Ltd
Original Assignee
Immuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuron Ltd filed Critical Immuron Ltd
Publication of CA3017477A1 publication Critical patent/CA3017477A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39508—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from milk, i.e. lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
CA3017477A 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder Abandoned CA3017477A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17292209P 2009-04-27 2009-04-27
US61/172,922 2009-04-27
CA2760096A CA2760096C (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2760096A Division CA2760096C (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.

Publications (1)

Publication Number Publication Date
CA3017477A1 true CA3017477A1 (en) 2010-11-04

Family

ID=42357536

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3017477A Abandoned CA3017477A1 (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
CA2760096A Expired - Fee Related CA2760096C (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2760096A Expired - Fee Related CA2760096C (en) 2009-04-27 2010-04-27 Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.

Country Status (14)

Country Link
US (2) US10117930B2 (https=)
EP (2) EP3461840A1 (https=)
JP (1) JP5740390B2 (https=)
KR (1) KR101785120B1 (https=)
AU (1) AU2010243205B2 (https=)
BR (1) BRPI1014774A2 (https=)
CA (2) CA3017477A1 (https=)
DK (1) DK2424890T3 (https=)
EA (1) EA024697B1 (https=)
ES (1) ES2684696T3 (https=)
IL (1) IL215924B (https=)
MX (1) MX2011011376A (https=)
SG (1) SG175142A1 (https=)
WO (1) WO2010125565A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808361A1 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of inflammatory bowel disease
AU2011313811A1 (en) * 2010-10-04 2013-01-31 Immuron Limited Methods and compositions using anti-lps ligands for the treatment and prevention of inflammatory disorders
MX340019B (es) 2010-11-23 2016-06-22 Pantheryx Inc Composiciones y metodos para el tratamiento en aplicaciones clinicas de amplio espectro, no diferenciadas o combinadas.
DE102011006781A1 (de) * 2011-04-05 2012-10-11 Mat-Malta Advanced Technologies Limited Antikörperprodukt, umfassend n spezifische Antikörper
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
WO2012171077A1 (en) * 2011-06-17 2012-12-20 Immuron Limited Method and composition for treatment or inhibition of mucositis associated with chemotherapy or radiation damage
WO2013009843A1 (en) * 2011-07-11 2013-01-17 Camas Incorporated Compositions against bacterial toxins
AU2013204801B2 (en) 2012-05-23 2014-11-06 Omniblend Innovation Pty Ltd Composition and method for management of diabetes or pre-diabetes
LT2864346T (lt) * 2012-06-21 2019-01-25 Synthon Biopharmaceuticals B.V. Antikūnų gryninimo metodas
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
HUE052599T2 (hu) 2013-05-03 2021-05-28 Selecta Biosciences Inc CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények
WO2015063693A1 (en) * 2013-10-30 2015-05-07 Hadasit Medical Research Services And Development Limited Anti-lps enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
JP6590413B2 (ja) 2014-02-06 2019-10-16 エックスフォー・ファーマシューティカルズ（オーストリア）ゲーエムべーハー 大腸菌特異的抗体配列
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
AU2015311704B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US20190134096A1 (en) * 2016-05-06 2019-05-09 Hadasit Medical Research Services & Development Limited Hyperimmune colostrum in the modulation and treatment of conditions associated with the mammalian microbiome
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
WO2018169811A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
EP3817564A4 (en) * 2018-07-02 2022-03-23 PureTech LYT, Inc. MILK VESICLES INTENDED FOR THE ADMINISTRATION OF BIOLOGICAL AGENTS
US10973918B2 (en) * 2018-10-03 2021-04-13 Anubis Bio Corporation Composition and methods for treating acute diarrhea and enteric infections in animals
EP3890748A4 (en) * 2018-12-05 2022-12-21 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
US12263192B2 (en) 2019-02-26 2025-04-01 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
CR20210522A (es) 2019-03-18 2021-12-17 Janssen Pharmaceuticals Inc Bioconjugados de antígenos–polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
IL286467B2 (en) 2019-03-18 2026-02-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of polysaccharides E. coli o-antigen, preparations thereof and methods for using them
CN114207440A (zh) 2019-06-04 2022-03-18 西莱克塔生物科技公司 聚乙二醇化尿酸酶的制剂和剂量
US20210252149A1 (en) * 2020-02-19 2021-08-19 Anubis Bio Corporation Composition and Methods for Treating Infectious Agents Using Pathogen-specific Antibodies
IL308201A (en) 2020-09-17 2024-01-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US12435125B2 (en) * 2021-04-16 2025-10-07 Prodigy Biotech Hyperimmunized egg product for treating or preventing alcoholic liver disease and graft- versus-host disease
KR20240082370A (ko) * 2021-09-30 2024-06-10 이구아루판 가부시키가이샤 모노클로널 항체 함유 조성물
AU2025233088A1 (en) * 2024-03-06 2026-04-02 Koru Biotech Solutions Limited Therapeutic and prophylactic agents and related compositions and methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627079A5 (en) 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
JPS58154513A (ja) * 1982-03-09 1983-09-14 Sendai Biseibutsu Kenkyusho 予防及び治療薬
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
GB9105292D0 (en) * 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
ATE234855T1 (de) 1993-09-20 2003-04-15 Anadis Ltd Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
DE4337654C2 (de) * 1993-11-04 1996-08-08 Biotest Pharma Gmbh Verwendung boviner Kolostralmilch von nicht mit Viren hyperimmunisierten Tieren als Leberschutzpräparat
BR9910725A (pt) 1998-05-27 2001-01-30 Gemma Biotechnology Ltd Indução de proteìnas e peptìdeos antibióticos por proteìnas lait/s cd14
DE19830607C2 (de) 1998-07-09 2002-08-01 Hte Ag The High Throughput Exp Verfahren zum Nachweis eines Produktes im Abstrom eines katalytischen Materials einer Vielzahl von katalytischen Materialien
KR20040106298A (ko) 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
WO2003097094A1 (en) 2002-05-21 2003-11-27 Anadis Ltd Method of prophylaxis of infection
US9701737B2 (en) 2003-02-19 2017-07-11 Camas, Incorporated Immunogen adherence and method of making and using same
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
EP2177229A3 (en) 2004-09-29 2010-11-03 Asama Chemical Co., Ltd. Functional composition or food comprising whey protein, antibody derived from milk or antibody
WO2006053383A1 (en) 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
EP2061510B1 (en) * 2006-08-31 2016-06-22 A.C.N. 135 493 391 Pty Ltd as trustee for Conca Unit Trust Treatment and/or prevention of barrett's esophagus using anti-ephb4 antibody-containing compositions
AU2009222965B2 (en) 2008-03-13 2014-10-02 Immuron Limited Immuno-modulating compositions for the treatment of immune-mediated disorders
CA2808361A1 (en) 2010-08-17 2012-02-23 Immuron Ltd. Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of inflammatory bowel disease

Also Published As

Publication number Publication date
JP2012525376A (ja) 2012-10-22
EA201171304A1 (ru) 2012-06-29
IL215924A0 (en) 2011-12-29
AU2010243205B2 (en) 2014-09-11
US20120135007A1 (en) 2012-05-31
CA2760096A1 (en) 2010-11-04
EP3461840A1 (en) 2019-04-03
IL215924B (en) 2018-01-31
WO2010125565A2 (en) 2010-11-04
DK2424890T3 (en) 2018-09-17
JP5740390B2 (ja) 2015-06-24
EA024697B1 (ru) 2016-10-31
SG175142A1 (en) 2011-12-29
ES2684696T3 (es) 2018-10-04
WO2010125565A3 (en) 2011-01-27
US10117930B2 (en) 2018-11-06
KR101785120B1 (ko) 2017-10-12
KR20120061067A (ko) 2012-06-12
EP2424890B1 (en) 2018-08-01
EP2424890A2 (en) 2012-03-07
AU2010243205A1 (en) 2011-12-01
CA2760096C (en) 2018-10-30
US20190209681A1 (en) 2019-07-11
MX2011011376A (es) 2012-04-20
BRPI1014774A2 (pt) 2019-04-16

Similar Documents

Publication Publication Date Title
CA2760096C (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder.
AU2009222965B2 (en) Immuno-modulating compositions for the treatment of immune-mediated disorders
DK2605791T3 (en) ANTI-LPS ENHANCED IMMUNOGLOBULIN PREPARATION FOR USE IN TREATMENT AND / OR PROPHYLAXY OF A PATHOLOGICAL DISORDER
HK40006401A (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
HK1163126A (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
HK1163126B (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
US10464998B2 (en) Anti-LPS enriched immunoglobulin for use in treatment and/or prophylaxis of fibrosis
JP4911894B2 (ja) 関節リウマチを予防するための経口投与用組成物
HK1185016B (en) Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
AU690521B2 (en) Anti-cholesterolemic egg, vaccine and method for production,and use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180914

FZDE Discontinued

Effective date: 20210108